FI118590B - 1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen - Google Patents

1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen Download PDF

Info

Publication number
FI118590B
FI118590B FI964332A FI964332A FI118590B FI 118590 B FI118590 B FI 118590B FI 964332 A FI964332 A FI 964332A FI 964332 A FI964332 A FI 964332A FI 118590 B FI118590 B FI 118590B
Authority
FI
Finland
Prior art keywords
prosthesis
migration
imidazol
ethane
hydroxy
Prior art date
Application number
FI964332A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI964332A0 (fi
FI964332A (fi
Inventor
Jonathan Green
Allen E Goodship
John Kenwright
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of FI964332A0 publication Critical patent/FI964332A0/fi
Publication of FI964332A publication Critical patent/FI964332A/fi
Application granted granted Critical
Publication of FI118590B publication Critical patent/FI118590B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI964332A 1994-05-04 1996-10-28 1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen FI118590B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9408775A GB9408775D0 (en) 1994-05-04 1994-05-04 Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
GB9408775 1994-05-04
IB9500288 1995-04-24
PCT/IB1995/000288 WO1995030421A1 (fr) 1994-05-04 1995-04-24 Utilisation de certains derives de l'acide methanebisphosphonique dans la prevention du relachement et de la migration de prothese

Publications (3)

Publication Number Publication Date
FI964332A0 FI964332A0 (fi) 1996-10-28
FI964332A FI964332A (fi) 1996-10-28
FI118590B true FI118590B (fi) 2008-01-15

Family

ID=10754497

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964332A FI118590B (fi) 1994-05-04 1996-10-28 1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen

Country Status (18)

Country Link
US (1) US5965547A (fr)
EP (1) EP0758241B1 (fr)
JP (1) JPH09512816A (fr)
AT (1) ATE218350T1 (fr)
AU (1) AU693541B2 (fr)
DE (1) DE69526937T2 (fr)
DK (1) DK0758241T3 (fr)
ES (1) ES2177642T3 (fr)
FI (1) FI118590B (fr)
GB (1) GB9408775D0 (fr)
HU (1) HUT74984A (fr)
IL (1) IL113566A (fr)
NO (1) NO310057B1 (fr)
NZ (1) NZ283430A (fr)
PT (1) PT758241E (fr)
TW (1) TW458779B (fr)
WO (1) WO1995030421A1 (fr)
ZA (1) ZA953537B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
GB2336311A (en) * 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
US6137012A (en) 1998-10-13 2000-10-24 E. I. Du Pont De Nemours And Company Phosphole and diphosphole ligands for catalysis
TR200101546T2 (tr) * 1998-12-04 2001-11-21 Roche Diagnostics Gmbh İç-protezlerde kemik entegrasyonunu iyileştirmek üzere ibandronat kullanılması.
EP1150684A4 (fr) * 1999-02-09 2005-06-15 Sloan Kettering Institutefor C Ciments osseux anti-resorption et implants osseux allogenes, autogreffes et xenogreffes
CN1319017A (zh) * 1999-08-02 2001-10-24 东丽株式会社 植入物的装入稳定剂
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
RU2288722C2 (ru) 2000-06-20 2006-12-10 Новартис Аг Способ введения бисфосфонатов
PL203087B1 (pl) * 2000-06-20 2009-08-31 Novartis Ag Zastosowanie kwasu 1-hydroksy-2-(imidazol-1-ilo)etano-1,1-difosfonowego albo jego farmaceutycznie dopuszczanej soli albo dowolnego hydratu
WO2002004038A1 (fr) * 2000-07-12 2002-01-17 Hopital Orthopedique De La Suisse Romande Revetement biologique actif pour implant osseux
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
CA2347330C (fr) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Preparation injectable liquide de pamidronate disodique
KR20140021045A (ko) * 2002-05-10 2014-02-19 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
CA2497353C (fr) * 2002-09-16 2012-08-28 Novartis Ag Methode de prevention ou de reduction de fractures secondaires consecutives a une fracture de la hanche
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
CA2669489A1 (fr) * 2006-11-17 2008-05-22 Besins Healthcare Compositions pharmaceutiques liquides contenant un compose biphosphonate
EP1958649A1 (fr) * 2007-02-14 2008-08-20 Graftys Ciment calcium-phosphate injectable libérant un inhibiteur de la résorption osseuse
EP2136814A4 (fr) * 2007-03-21 2012-05-30 Univ Duke Trousses de médication et formulations pour prévenir, traiter ou réduire des fractures secondaires après une fracture antérieure
WO2008152518A2 (fr) * 2007-05-16 2008-12-18 Actavis Group Ptc Ehf Procédé de préparation du risédronate sodique
SI2473172T1 (sl) 2009-09-01 2015-07-31 Duke University Bisfosfonat sestavki in postopki za zdravljenje srčne okvare
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
US9949992B2 (en) 2011-11-16 2018-04-24 Duke University Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
ES2038692T4 (es) * 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
JPH05163150A (ja) * 1991-05-13 1993-06-29 E R Squibb & Sons Inc アテローム性動脈硬化症の抑制・治療剤
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices

Also Published As

Publication number Publication date
ES2177642T3 (es) 2002-12-16
IL113566A (en) 2002-05-23
NZ283430A (en) 2000-06-23
FI964332A0 (fi) 1996-10-28
DE69526937T2 (de) 2003-01-02
PT758241E (pt) 2002-10-31
NO964486L (no) 1996-10-22
DE69526937D1 (de) 2002-07-11
HUT74984A (en) 1997-03-28
AU2146695A (en) 1995-11-29
NO310057B1 (no) 2001-05-14
JPH09512816A (ja) 1997-12-22
US5965547A (en) 1999-10-12
ZA953537B (en) 1995-11-06
IL113566A0 (en) 1995-08-31
EP0758241A1 (fr) 1997-02-19
TW458779B (en) 2001-10-11
WO1995030421A1 (fr) 1995-11-16
FI964332A (fi) 1996-10-28
GB9408775D0 (en) 1994-06-22
HU9603042D0 (en) 1997-01-28
NO964486D0 (no) 1996-10-22
ATE218350T1 (de) 2002-06-15
EP0758241B1 (fr) 2002-06-05
AU693541B2 (en) 1998-07-02
DK0758241T3 (da) 2002-09-23

Similar Documents

Publication Publication Date Title
FI118590B (fi) 1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
CN1078073C (zh) 二膦酸盐在矫形假体移植后在抑制骨再吸收中的应用
EP1296689B3 (fr) Methode d'administration de bisphosphonates
SK287501B6 (sk) Použitie kyseliny zoledrónovej na prípravu liečiva na liečenie bolesti
WO1996039107A1 (fr) Composition a base de ciment de bisphosphonate permettant d'eviter le relachement aseptique des protheses orthopediques
KR20150028861A (ko) 이식물 골유착을 개선하기 위한 방법 및 조성물
EP0600834A1 (fr) Utilisation de dérivés de l'acide méthanediphosphonique pour la fabrication d'un médicament pour le traitement de fractures
AU670337B2 (en) Use of certain methanebisphosphonic acid derivatives in fracture healing
Reginster Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review
Richardson et al. First place—resident basic science award 1993: Risedronate activity in the fetal and neonatal mouse
EP1591122B1 (fr) Méthode pour l'administration de biphosphonates
CA2183764C (fr) Utilisation de certains derives de l'acide methanebisphosphonique dans la prevention du relachement et de la migration de prothese
WO2002089768A1 (fr) Preparation liquide injectable de pamidronate disodique
RU2325170C1 (ru) Биокомпозиционный материал для остеопластики
MXPA96005327A (en) Use of certain derivatives of acidometanisphisphonic to prevent the loosening of protesis and the emigration of proteins
Shanbhag et al. Localized Osteolysis after Joint Replacement Surgery
MXPA96004968A (en) Use of bisphosphonates to inhibit bone rebassion after the implantation of orthopedic protesis
AU2005203308A1 (en) Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FG Patent granted

Ref document number: 118590

Country of ref document: FI